Latest News and Press Releases

Optigo Bio Wins People’s Choice Award at Eyecelerator and Presents Compelling Preclinical Data on Long-Acting Intravitreal Biologics at ARVO 2025

RetinalGenix Technologies to Participate at 2025 Roth Conference and will discuss patented remote monitoring high-resolution retinal imaging and biomarkers

RETINALGENIX TECHNOLOGIES BREAKTHROUGH IN REAL-TIME 24/7 REMOTE OCULAR MONITORING High-Resolution Retinal Imaging Using Both Near Infrared And Green Modes

ANN ARBOR, Mich., Feb. 04, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...

New York, United States, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The eye’s macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision...

ANN ARBOR, Mich., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...

Dublin, Oct. 03, 2024 (GLOBE NEWSWIRE) -- The "Intraocular Lens (IOL) - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global Intraocular Lens (IOL) market...

ANN ARBOR, Mich., Sept. 13, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...

ANN ARBOR, Mich., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...

Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 (Study Record |...